Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE: Neurology and Therapy

T. Alsaadi, D.M. Kayed, A. Al-Madani, A.M. Hassan, A. Terruzzi, D. Krieger, N. Riachi, P. Sarathchandran, S. Al-Rukn

    Research output: Contribution to journalArticlepeer-review

    1 Scopus citations


    Introduction: Migraine is a common debilitating neurological disorder affecting a large proportion of the general population. Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, plays a key role in the pathophysiology of migraine, and the development of therapies targeting the anti-CGRP pathway has revolutionized the field of migraine treatment. Methods: An expert task force of neurologists in the United Arab Emirates (UAE) developed and critically assessed recommendations on the use of CGRP-based therapies in migraine treatment and management in the UAE, based on available published literature. A consensus was reached for each statement by means of an open-voting process, based on a predefined agreement level of at least 60%. Results: The consensus recommendations advocate the need for guidelines for the appropriate use of CGRP-based therapies by defining patient cohorts and appropriate monitoring of therapeutic response as well as standardizing the initiation, assessment, and cessation of treatment. The consensus recommendations were primarily formulated on the basis of international studies, because of the limited availability of regional and local data. As such, they may also act as guidelines for global healthcare providers. Conclusions: These are the first consensus recommendations for the UAE that address the use of CGRP-based therapies in the treatment and management of migraine, integrating both clinical evidence and medical expertise to enhance clinical judgment and decision-making. © 2023, The Author(s).
    Original languageBritish English
    Pages (from-to)1845-1865
    Number of pages21
    JournalNeurol. Ther.
    Issue number6
    StatePublished - 2023


    • CGRP-based therapy
    • Consensus recommendations
    • Gepants
    • Migraine
    • United Arab Emirates (UAE)
    • atogepant
    • calcitonin gene related peptide
    • eptinezumab
    • erenumab
    • fremanezumab
    • galcanezumab
    • monoclonal antibody
    • rimegepant
    • ubrogepant
    • zavegepant
    • American headache society
    • Article
    • consensus
    • decision making
    • expert task force
    • Food and Drug Administration
    • gastrointestinal motility
    • GRADE approach
    • health care
    • health care personnel
    • human
    • medical expertise
    • medical society
    • MIDAS (migraine)
    • migraine
    • observational study
    • practice guideline
    • quality control
    • quality of life
    • randomized controlled trial (topic)
    • systematic review
    • task performance
    • treatment response
    • United Arab Emirates


    Dive into the research topics of 'Consensus-Based Recommendations on the Use of CGRP-Based Therapies for Migraine Prevention in the UAE: Neurology and Therapy'. Together they form a unique fingerprint.

    Cite this